# Migraine FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/migraine

> 14 upcoming FDA catalysts in migraine: MEDI0618 (ABBV) on February 2027 (primary completion); MEDI0618 (ABBV) on Feb to May 2027 (topline data readout); Ubrelvy (ubrogepant, ABBV) on May 2027 (primary completion); Ubrelvy (ubrogepant, ABBV) on May to Aug 2027 (topline data readout); and 10 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 30, 2025 | [Zavzpret ® (zavegepant) primary completion](https://sec-api.dev/pdufa/zavegepant) | PFE | Migraine | completed | "NCT05989048 (A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05989048)) |
| July 7, 2025 | [Qulipta (atogepant) primary completion](https://sec-api.dev/pdufa/atogepant) | ABBV | Migraine | completed | "NCT06241313 (Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06241313)) |
| August 15, 2025 | [AJOVY® (fremanezumab) primary completion](https://sec-api.dev/pdufa/fremanezumab) | TEVA | Migraine | completed | "NCT04530110 (A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-15 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC; Results First Posted 2026-07-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04530110)) |
| August 25, 2025 | [Nurtec Odt (rimegepant sulfate) primary completion](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | completed | "NCT05810038 (A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-09-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05810038)) |
| November 12, 2025 | [Reyvow (lasmiditan succinate) primary completion](https://sec-api.dev/pdufa/lasmiditan) | LLY | Migraine | withdrawn | "NCT04396236 (A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04396236)) |
| November 19, 2025 | [Erenumab dose 1 primary completion](https://sec-api.dev/pdufa/erenumab) | AMGN | Migraine | completed | "NCT03836040 (Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-19 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03836040)) |
| December 4, 2025 | [Reyvow (lasmiditan succinate) primary completion](https://sec-api.dev/pdufa/lasmiditan) | LLY | Migraine | withdrawn | "NCT04396574 (A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-12-04 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-25." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04396574)) |
| May 22, 2026 | [Zavzpret ® (zavegepant) topline data readout](https://sec-api.dev/pdufa/zavegepant) | PFE | Migraine | completed | "NCT05989048 (A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-05-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05989048?tab=results)) |
| July 24, 2026 | [AJOVY® (fremanezumab) topline data readout](https://sec-api.dev/pdufa/fremanezumab) | TEVA | Migraine | completed | "NCT04530110 (A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-15 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC; Results First Posted 2026-07-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04530110?tab=results)) |
| September 3, 2026 | [Nurtec Odt (rimegepant sulfate) topline data readout](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | completed | "NCT05810038 (A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-09-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05810038?tab=results)) |
| February 2027 | [MEDI0618 primary completion](https://sec-api.dev/pdufa/medi0618) | ABBV | Migraine | scheduled | "NCT06602479 (A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602479)) |
| Feb to May 2027 | [MEDI0618 topline data readout](https://sec-api.dev/pdufa/medi0618) | ABBV | Migraine | scheduled | "NCT06602479 (A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602479)) |
| May 2027 | [Ubrelvy (ubrogepant) primary completion](https://sec-api.dev/pdufa/ubrogepant) | ABBV | Migraine | scheduled | "NCT05125302 (Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05125302)) |
| May to Aug 2027 | [Ubrelvy (ubrogepant) topline data readout](https://sec-api.dev/pdufa/ubrogepant) | ABBV | Migraine | scheduled | "NCT05125302 (Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05125302)) |
| October 2027 | [Evo756, dose 1 primary completion](https://sec-api.dev/pdufa/evo756) | EVMN | Migraine | scheduled | "NCT07616128 (Study of EVO756 in Adults With Migraine): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Evommune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07616128)) |
| Oct 2027 to Jan 2028 | [Evo756, dose 1 topline data readout](https://sec-api.dev/pdufa/evo756) | EVMN | Migraine | scheduled | "NCT07616128 (Study of EVO756 in Adults With Migraine): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Evommune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07616128)) |
| November 2027 | [Ubrelvy (ubrogepant) primary completion](https://sec-api.dev/pdufa/ubrogepant) | ABBV | Migraine | scheduled | "NCT06417775 (Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06417775)) |
| Nov 2027 to Feb 2028 | [Ubrelvy (ubrogepant) topline data readout](https://sec-api.dev/pdufa/ubrogepant) | ABBV | Migraine | scheduled | "NCT06417775 (Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06417775)) |
| January 2028 | [Ubrelvy (ubrogepant) primary completion](https://sec-api.dev/pdufa/ubrogepant) | ABBV | Migraine | scheduled | "NCT05127954 (Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05127954)) |
| Jan to Apr 2028 | [Ubrelvy (ubrogepant) topline data readout](https://sec-api.dev/pdufa/ubrogepant) | ABBV | Migraine | scheduled | "NCT05127954 (Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05127954)) |
| Mar to Jun 2029 | [Nurtec Odt (rimegepant sulfate) topline data readout](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | scheduled | "NCT05156398 (Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-27 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05156398)) |
| March 2029 | [Nurtec Odt (rimegepant sulfate) primary completion](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | scheduled | "NCT05156398 (Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-27 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05156398)) |
| Feb to May 2030 | [Nurtec Odt (rimegepant sulfate) topline data readout](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | scheduled | "NCT06616194 (A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-02-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06616194)) |
| February 2030 | [Nurtec Odt (rimegepant sulfate) primary completion](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | scheduled | "NCT06616194 (A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-02-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06616194)) |

## Drugs

- [Zavzpret ® (zavegepant)](https://sec-api.dev/pdufa/zavegepant) (PFE)
- [Qulipta (atogepant)](https://sec-api.dev/pdufa/atogepant) (ABBV)
- [AJOVY® (fremanezumab)](https://sec-api.dev/pdufa/fremanezumab) (TEVA)
- [Nurtec Odt (rimegepant sulfate)](https://sec-api.dev/pdufa/rimegepant) (PFE)
- [Reyvow (lasmiditan succinate)](https://sec-api.dev/pdufa/lasmiditan) (LLY)
- [Erenumab dose 1](https://sec-api.dev/pdufa/erenumab) (AMGN)
- [MEDI0618](https://sec-api.dev/pdufa/medi0618) (ABBV)
- [Ubrelvy (ubrogepant)](https://sec-api.dev/pdufa/ubrogepant) (ABBV)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/migraine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Migraine FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/migraine

```bibtex
@misc{secapidev_indications_migraine_20261116,
  title        = {Migraine FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/migraine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_migraine_20261116","title":"Migraine FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/migraine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
